Dr. Brian Philip

Principal Cell and Gene Therapy Scientist

Dr. Brian Philip is NIBRT Principal Cell and Gene Therapy Scientist, providing substantial strategic and scientific direction to accelerate advanced therapy research programmes at CONCEPT and NIBRT.

Brian is an accomplished scientist with over 15 years’ experience in adoptive cellular immunotherapy. He completed his PhD at University College London under the guidance of Dr. Martin Pule, where he developed the RQR8 cell therapy safety-switch, which has progressed into clinical application under commercial licence from UCLB. During his EU ATECT consortium postdoctoral research, he was involved with translational development of the Cellectis Therapeutics UCART19 programme. With significant advances in the field, Brian’s findings have been published in eminent journals including Nature Medicine, Cancer Discovery and Blood. Brian next leveraged his experience to accelerate translational development of off-the-shelf allogeneic immunotherapies at TC BioPharm and Triumvira Immunologics. His expertise extends from early-stage synthetic biology and cellular engineering, through to translational process development and commercial drug development. In 2023, Brian’s appointment to NIBRT was announced, he has since worked closely with scientists and clinicians to shape the advanced therapy research and development landscape.